RESUMEN
BACKGROUND: There is still controversy about which preservation solution in pancreas transplantation could be the best. The aim of this study was to analyze our initial experience with Custodiol solution (CuS) compared with Viaspan solution (VS) and Celsior solution (CS) in pancreas transplantation. METHODS: A retrospective study included 94 consecutive pancreatic transplants, from 2007 until 2015. We compared 3 groups, depending on preservation solution: Viaspan (n = 41), Celsior (n = 40), or Custodiol (n = 13). The primary end point was patient and pancreas survival at 1 year after pancreas transplantation. RESULTS: The recipient and donor characteristics were similar except in cold ischemia time; it was higher with Celsior. No differences were found in postoperative complications and pancreas graft function at 3 months, 6 months, and 1 year (glucose, HbA1c, C-peptide, creatinine). The pancreas and patient survival at 1 year was comparable (pancreas survival: VS, 80%; CS, 90%; CuS, 92%; log-rank, 0.875; and patient survival: VS, 92%; CS, 97%; CuS, 100%; log-rank, 0.9). CONCLUSIONS: In our institution, the Custodiol solution in pancreas transplantation presented similar outcomes in terms of postoperative complications, pancreas graft function, and 1-year survival.
Asunto(s)
Soluciones Preservantes de Órganos/farmacología , Trasplante de Páncreas/métodos , Adenosina/farmacología , Adulto , Alopurinol/farmacología , Glucemia/metabolismo , Péptido C/metabolismo , Isquemia Fría , Disacáridos/farmacología , Electrólitos/farmacología , Femenino , Glucosa/farmacología , Glutamatos/farmacología , Glutatión/farmacología , Supervivencia de Injerto/efectos de los fármacos , Histidina/farmacología , Humanos , Insulina/farmacología , Masculino , Manitol/farmacología , Preservación de Órganos/métodos , Páncreas/efectos de los fármacos , Páncreas/fisiología , Trasplante de Páncreas/mortalidad , Cloruro de Potasio/farmacología , Procaína/farmacología , Estudios Prospectivos , Rafinosa/farmacología , Estudios Retrospectivos , Donantes de Tejidos/estadística & datos numéricosRESUMEN
INTRODUCTION: In patients who receive a kidney transplant from expanded criteria donors (ECDs), few studies are available concerning the relation between the clinical characteristics, pretransplant biopsies, and graft outcomes. AIM: To identify early clinical markers predicting worse graft survival in recipients of kidneys from ECDs. MATERIALS AND METHODS: Between 1999 and 2006, we performed a prospective, observational study in 180 recipients of kidney grafts from ECDs that had undergone a preoperative biopsy to evaluate viability. The patients received immunosuppression with basiliximab, late introduction of tacrolimus, mycophenolate mofetil, and steroids. Data were gathered on demographic and posttransplantation clinical characteristics at 1, 3, 6, and 9 months, including estimates of proteinuria and of the glomerular filtration rate using the Modification of Diet in Renal Disease (MDRD) formula. RESULTS: The mean age of the donors was 63.54 years and of the recipients, 58.38 years. A creatinine clearance below the median (40 mL/min, interquartile range 32-50 mL/min) in the first posttransplant year was significantly associated with worse death-censored graft survival (log-rank 14.22, P<.0001). A proteinuria value above the median (100 mg/24 h, interquartile range 40-275 mg/24 h) at 1 year posttransplant significantly reduced the death-censored graft survival (log-rank 14.3, P<.0001). Multivariate Cox analysis showed that a creatinine clearance<40 mL/min in the first year (hazards ratio [HR] 5.7, 95% Confidence Interval [CI] 1.62-20.37; P=.007) and proteinuria at 1 year greater tan 100 mg/24 h (HR 8.3, 95% CI 2.15-32.06; P=.002) were independent risk factors for death-censored graft loss after adjusting for donor age and acute rejection episodes. CONCLUSIONS: Limited renal function and/or low proteinuria at 1 year posttransplant were associated with worse kidney graft survival among recipients of kidneys from ECDS.
Asunto(s)
Creatinina/orina , Supervivencia de Injerto , Trasplante de Riñón , Proteinuria/diagnóstico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Análisis de SupervivenciaRESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Crioglobulinemia/complicaciones , Trasplante de Riñón , Hepatitis C Crónica/complicaciones , Diálisis Renal , Insuficiencia Renal Crónica/terapiaRESUMEN
Among the numeruos adverse side effects of tacrolimus (TAC), de novo thrombotic microangiopathy stands out as an infrecuente but severe complication. Renal dysfunction is the only alteration that should lead to suspicion of thrombotic microangiopathy, because the clinical features of intravascular hemolysis are not always found. The definitive diagnosis can usually be made with kidney biopsy. Patientes with TAC induced thrombotic microangiopathy usually promptly recover after treatment withdrawal or reduction in the dose of TAC and a short course of plasma therapy, but the risk of rejection increases. Switching from TAC to cyclosporine has also been tried with resolution of the hemolysis but thrombotic microangiopathy has been noted with both and this condition may later recur. We present a 29-year-old man who received a kidney-pancreas transplant for end-stage diabetic nephropathy. After initial induction with basiliximab, the immunosuppression consisted of prednisone, tacrolimus and mycophenolate mofetil. Twenty four days posttransplantation his renal function declined with a peak creatine level of 2.35 mg/dl. Laboratory studies showed thrombocytopenia and features of intravascular hemolysis. TAC associated hemolytic uremic syndrome was suspected and drug was immediately stopped and converted to sirolimus. Also he was treated with plasma infusion. The allograft biopsy showed focal glomerular and arteriolar acute thrombosis without evidence of rejection. Our experience demostrate that switching from tacrolimus to sirolimus could be an adecuate strategy for patients who develop FK506-associated de novo thrombotic microangiopathy without increase risk of acute rejection.
Asunto(s)
Síndrome Hemolítico-Urémico/inducido químicamente , Inmunosupresores/efectos adversos , Trasplante de Riñón , Ácido Micofenólico/análogos & derivados , Trasplante de Páncreas , Complicaciones Posoperatorias/inducido químicamente , Proteínas Recombinantes de Fusión , Tacrolimus/efectos adversos , Adulto , Anticuerpos Monoclonales/uso terapéutico , Basiliximab , Diabetes Mellitus Tipo 1/complicaciones , Diabetes Mellitus Tipo 1/cirugía , Nefropatías Diabéticas/complicaciones , Quimioterapia Combinada , Duodenostomía , Síndrome Hemolítico-Urémico/patología , Síndrome Hemolítico-Urémico/terapia , Humanos , Yeyunostomía , Fallo Renal Crónico/etiología , Fallo Renal Crónico/cirugía , Necrosis Tubular Aguda/etiología , Masculino , Ácido Micofenólico/uso terapéutico , Fístula Pancreática/etiología , Plasma , Complicaciones Posoperatorias/patología , Complicaciones Posoperatorias/terapia , Prednisona/uso terapéutico , Sirolimus/uso terapéuticoRESUMEN
El síndrome hemolítico urémico, de novo es la forma más severa de toxicidad aguda producida por los anticalcineurínicos. La retirada del fármaco puede resolver el cuadro, pero aumenta el riesgo de pérdida del injerto por rechazo agudo. En estos casos, la conversión a sirolimus puede ser la solución, ya que nos permite mantener una inmunosupresión eficaz en la prevención del rechazo agudo carente de toxicidad sobre las células endoteliales. Se presenta un paciente de 29 años trasplantado de riñón-páncreas, tratado con tacrolimus que desarrolla esta complicación en el postoperatorio y que se resuelve con la conversión a sirolimus y la administración de plasma fresco. En conclusión, la presencia de determinados datos clínicos y analíticos, en conjunto, nos permiten una orientación inicial para el diagnóstico diferencial entre ambas entidades (AU)
Among the numeruos adverse side effects of tacrolimus (TAC), de novo thrombotic microangiopathy stands out as an infrecuente but severe complication. Renal dysfunction is the only alteration that should lead to suspicion of thrombotic microangiopathy, because the clinical features of intravascular hemolysis are not always found. The definitive diagnosis can usually be made with kidney biopsy. Patientes with TAC induced thrombotic microangiopathy usually promptly recover after treatment withdrawal or reduction in the dose of TAC and a short course of plasma therapy, but the risk of rejection increases. Switching from TAC to cyclosporine has also been tried with resolution of the heolysis but thrombotic microangiopathy has been noted with both and this condition may later recur. We present a 29-year-old man who received a kidney-pancreas transplant for end-stage diabetic nephropathy. After initial induction with basiliximab, the immunosuppression consisted of prednisone, tacrolimus and mycophenolate mofetil. Twenty four days posttransplantation his renal function declined with a peak creatine level of 2.35 mg/dl. Laboratory studies showed thrombocytopenia and features of intravascular hemolysis. TAC associated hemolytic uremic syndrome was suspected and drug was immediately stopped and converted to sirolimus. Also he was treated with plasma infusion. The allograft biopsy showed focal glomerular and arteriolar acute thrombosis without evidence of rejection. Our experience demostrate that switching from tacrolimus to sirolimus could be an adecuate strategy for patients who develop FK506-associated de novo thrombotic microangiopathy without increase risk of acute rejection (AU)